carcinoid tumor/diarreia

O link é salvo na área de transferência

Escolha o tipo de classificação

Página 1 a partir de 410 resultados

Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

OBJECTIVE Telotristat ethyl (TE) was recently approved for carcinoid syndrome diarrhea (CSD) in patients not adequately controlled with somatostatin analog long-acting release (SSA LAR) therapy alone. A budget impact model was developed to determine the short-term affordability of reimbursing TE in

Pharmacoeconomic Review Report: Telotristat Ethyl (Xermelo): (Ipsen Biopharmaceuticals Canada Inc.): Indication: Refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients inadequately controlled by SSA therapy alone

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

Telotristat ethyl (Xermelo) is a tryptophan hydrolase inhibitor indicated for the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients whose condition is inadequately controlled by SSA therapy alone. Carcinoid syndrome occurs in

Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron, and clonidine.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

A 69-yr-old man with known carcinoid syndrome treated with octreotide and interferon-alpha 2b developed diarrhea, with six to eight watery to semiliquid stools per day. Diminished stool frequency and increased stool consistency were obtained by treatment with the 5-hydroxytryptamine-3 receptor

Evidence-Based Policy in Practice: Management of Carcinoid Syndrome Diarrhea.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

Carcinoid syndrome causes substantial morbidity and reduces quality of life and survival. In a recent clinical trial, 97% of patients reported bowel movement-related issues, abdominal pain, flushing, and low energy. Combining somatostatin analogs with elotristat ethyl provides a new option for

Clinical Review Report: Telotristat (Xermelo): (Ipsen Biopharmaceuticals Canada Inc.): Indication: For the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients inadequately controlled by SSA therapy alone

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

The objective of this report is to perform a systematic review of the beneficial and harmful effects of telotristat ethyl for the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients whose disease inadequately controlled by SSA

Effect of somatostatin infusion on jejunal water and electrolyte transport in a patient with secretory diarrhea due to malignant carcinoid syndrome.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

The effect of intravenous somatostatin infusion was investigated in a patient with severe secretory diarrhea due to malignant carcinoid syndrome. Continuous somatostatin infusion for 48 hr (4 microgram/kg/hr) reduced stool volume from 2.2 to 0.7 liters/day. Intestinal perfusion studies before

A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

OBJECTIVE Carcinoid patients show a hypertonic colonic motor response postprandially. Ondansetron reduces postprandial colonic tone in health. It was hypothesized that ondansetron, a selective 5HT3 antagonist, corrects the colonic motor response to eating in carcinoid diarrhea. METHODS The effects

Relation between fat malabsorption and transit abnormalities in human carcinoid diarrhea.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

OBJECTIVE Fat and complex carbohydrates in the distal bowel activate "brakes" inhibiting upper gut motility. The hypothesis of this study was that rapid transit carcinoid diarrhea in association with steatorrhea results in impairment of gastric emptying. METHODS Fifteen patients with carcinoid

Rectal Mechano-sensory Function in Patients with Carcinoid Diarrhea.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

OBJECTIVE In patients with neuroendocrine tumors, excessive production of serotonin and other amines may cause the carcinoid syndrome,which is mainly characterized by diarrhea and flushing. Little is known about the pathophysiology of carcinoid diarrhea. In severalother groups of patients, diarrhea

5-HTP induced diarrhea as a carcinoid syndrome model in mice?

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

Serotonin (5-HT) is present in the gastrointestinal tract and is probably one of the compounds responsible for diarrhea in patients presenting with carcinoid syndrome. Intraperitoneal administration of L-5-hydroxytryptophan (L-5-HTP) at doses of 25 to 100 mg/kg dramatically increase defecation in

Telotristat ethyl for the treatment of carcinoid syndrome diarrhea not controlled by somatostatin analogues.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

Telotristat ethyl (Xermelo), developed by Lexicon Pharmaceuticals, is an oral tryptophan hydroxylase inhibitor blocking peripheral conversion of tryptophan to serotonin (5-hydroxytryptamine [5-HT]). It was approved by the U.S. Food and Drug Administration (FDA) in February 2017 and by the European

Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

Carcinoid syndrome (CS), characterized by diarrhea and flushing, is present in 20% of patients with neuroendocrine tumors at diagnosis and becomes more frequent with progression. The diarrhea of CS is caused mainly by tumoral secretion of serotonin. It may not be fully controlled by somatostatin

Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

BACKGROUND Metastatic neuroendocrine tumors (NETs) are associated with carcinoid syndrome that is typically characterized by diarrhea, cutaneous flushing and bronchospasm. Treatment with somatostatin analogues (SSA) improves the symptom burden but a significant proportion of patients stop responding

Resolution of chronic diarrhea after resection of a localized pulmonary carcinoid tumor.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

Pulmonary carcinoid tumors are rarely associated with symptoms of the carcinoid syndrome, such as flushing and diarrhea. When present, these symptoms virtually always represent extensive hepatic metastases. In this article we describe the presentation, perioperative management, and presumed

Regional Gastrointestinal Transit Times in Patients With Carcinoid Diarrhea: Assessment With the Novel 3D-Transit System.

Apenas usuários registrados podem traduzir artigos

Entrar Inscrever-se

OBJECTIVE The paucity of knowledge regarding gastrointestinal motility in patients with neuroendocrine tumors and carcinoid diarrhea re-stricts targeted treatment. 3D-Transit is a novel, minimally invasive, ambulatory method for description of gastrointestinal motility. The system has not yet been

Junte-se à nossa
página do facebook

Herbal & Natural Medicine

O mais completo banco de dados de ervas medicinais apoiado pela ciência

Funciona em 55 idiomas
Curas herbais apoiadas pela ciência
Reconhecimento de ervas por imagem
Mapa GPS interativo - marcar ervas no local (em breve)
Leia publicações científicas relacionadas à sua pesquisa
Pesquise ervas medicinais por seus efeitos
Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes

Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas